Αρχική World News FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC World News FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC Από Ogkologos - 18 Μαρτίου, 2026 435 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Easing Concerns about Giving Research Study Participants Their Genetic Test Results 1 Ιουνίου, 2018 From Scan to Scan: The Challenges of Living with Metastatic Cancer 15 Οκτωβρίου, 2021 Pembrolizumab Improves Survival in Advanced Triple-Negative Breast Cancer 9 Αυγούστου, 2022 Breast Cancer Survivor Thanks Early Detection For Saving Her Life 6 Απριλίου, 2021 Φόρτωση περισσοτέρων HOT NEWS This Company Is Turning Scrap Wood Into 10,000+ Guitars For Sick... 27-Year-Old Thought She Was Injured Falling Off A Horse, But Then... 6-Year-Old Uses Money From Lemonade Stand To Take Mom Out On... New Technology System Allows Patients To Get A Mammogram And Biopsy...